Abstract. *Pseudostellaria heterophylla* (Miquel) Pax has various pharmacological effects that include immunologic enhancement and anti-oxidation. However, it remains unclear whether PH exerts beneficial effects in dermatological diseases. The present study examined the effects of PH on a 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD) mouse model and elucidated its underlying mechanism of action. PH extract (1 and 100 mg/ml) was applied topically to DNCB-treated dorsal skin of mice every day for 11 days. The immunomodulatory effects of PH were evaluated by measuring skin thickness, mast cell infiltration, serum levels of immunoglobulin E (IgE), and mRNA expression levels of T helper (h)1/Th2 and pro-inflammatory cytokines in dorsal skin. In addition, cluster of differentiation (CD)4⁺ T cells were detected in dorsal skin by immunohistochemistry. Topical application of PH significantly reduced the thickness of dermis, epidermis and serum IgE production compared with the DNCB group. PH treatment inhibited infiltration of inflammatory cells, including mast cells and CD4⁺ T cells, and suppressed the mRNA expression levels of cytokines (interferon-γ, interleukin-4, -6, -8 and -1β, and tumor necrosis factor-α) associated with the immune response. Furthermore, PH treatment significantly downregulated the protein expression levels of nuclear factor-kB, phosphorylated inhibitor of kBα and mitogen-activated protein kinases. The results suggested that PH may be a potential therapeutic strategy for the treatment of AD via the modulation of Th1 and Th2 levels.

Introduction

Atopic dermatitis (AD) involves a complex immune response mediated by T helper (Th) 1 and Th2 T cell subsets (1). Chronic skin lesions of AD are dominated by Th1-type cytokine responses with high levels of interferon (IFN)-γ. The Th2-type cytokines, interleukin (IL)-4, -6 and -13, serve important roles in the increase in the levels of serum immunoglobulin E (IgE) and mast cells during AD development (2). Therefore, Th1 and Th2 cytokines may contribute to AD lesions (3).

The topical application of steroids is typically recommended for the treatment of AD (4). However, topical steroids have various well-known adverse effects, including skin atrophy, a tendency for bruising, tachyphylaxis and the rebound phenomenon (5). Therefore, herbal medicines have been investigated as potential topical agents for the treatment of AD.

*Pseudostellaria heterophylla* (Miquel) Pax has been described as a type of ‘qi-enriching and tonic drug’ (6), which has a beneficial effect for the immune system (7). In addition, *Pseudostellaria heterophylla* (PH) has mild toning effects on the body, leading to its widespread use in herbal medicines and healthcare products (8,9). The primary components of PH include polysaccharides, cycle peptides, amino acids, volatile compounds, saponins, amino acids and minerals. In particular, macromolecule polysaccharides are considered to be the primary active component of PH (10). Previous studies have suggested that PH has immunomodulatory, anti-inflammatory and anti-oxidant properties (7,11). These diverse biological activities may be beneficial for the treatment of AD.

The present study therefore aimed to evaluate the immunomodulatory activity of PH water extracts in a 2,4-dinitrochlorobenzene (DNCB)-induced mouse model of AD.

Materials and methods

Preparation of sample. PH was supplied by Jung-do Herb Inc. (Guri, Korea) and was authenticated by
Professor Woong Mo Yang (Kyung Hee University, Seoul, Korea). The crude drug (100 g) was extracted with 1,000 ml distilled water for 24 h at room temperature. Following filtration, the extracted solution was concentrated in a rotary evaporator, freeze-dried, and stored in aliquots at -70°C. The yield from the dried roots was 23.09%. The authenticated voucher specimens (no. PH131201) were stored in the College of Pharmacy of Kyung Hee University. The PH extracts was dissolved in distilled water immediately prior to use.

Animal model. A total of 25 female BALB/c mice (age, 6 weeks; weight, 18-22 g) were obtained from Raon Bio Inc. (Yongin, Korea) and housed in an air-conditioned room at a temperature of 23±1°C and relative humidity of 60±5%, under a 12-h light/dark cycle. During the experimental period, all mice received standard mouse chow and water ad libitum. All experiments were conducted according to the guidelines of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by Committee on Care and Use of Laboratory Animals of the Kyung Hee University (approval no. KHUASP (SE)-14-030; Seoul, Korea). Following an acculturation period of 1 week, mice were randomly divided into five groups (n=5): NOR, in which mice were challenged with vehicle treatment as a baseline control; DNCB, in which mice were sensitized with 100 µl/day 1 or 0.5% DNCB (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) as negative control; DEX, in which mice were topically treated with 100 µl/day 10 µM dexamethasone (DEX; Sigma-Aldrich; Merck Millipore) following DNCB sensitization as positive control; PH1, in which mice were topically treated with 100 µl/day 1 mg/ml PH following DNCB sensitization; and PH100, in which mice were topically treated with 100 µl/day 100 mg/ml PH following DNCB sensitization.

To induce dermatitis, 100 µl 1% DNCB solution [in acetone: olive oil at a ratio of 4:1 (v/v)] was applied onto the shaved dorsal skin of all mice excluding the NOR group once a day for 3 days (day 1-3). Following the first challenge, mice were left untreated for 4 days (day 4-7). In the second challenge, PH (1 or 100 mg/ml) or DEX was topically applied to mice prior to the application of 0.5% DNCB for 11 consecutive days (day 8 to day 18). An equal volume of vehicle was applied to the NOR group at the same time points. All animals were sacrificed 24 h after the last treatment (day 19) under anesthesia with intraperitoneal injection of a tiletamine/zolazepam mixture (30 mg/kg, Zoletil 50; Virbac Lab, Carros, France). Serum was collected by cardiac puncture and the dorsal skin of mice was biopsied for histopathology and measurement of tissue cytokines levels.

Histopathology. To evaluate skin thickening and mast cell infiltration, the dorsal skin samples (1x0.4 cm²) were prepared at sacrifice (day 19). Samples were fixed in 10% buffered formalin (Sigma-Aldrich; Merck Millipore), embedded in paraffin and cut into 4-µm thick sections. Following dewaxing and dehydration of paraffin sections, hematoxylin and eosin staining was performed to assess skin thickening and toluidine blue staining to detect mast cells as previously described (12). Histopathological alterations were examined using the Leica Application Suite (LAS; Leica Microsystems, Inc., Buffalo Grove, IL, USA) and viewed at magnification, x100. Skin thickness was measured in >5 fields, at intervals of 200 µm, in each sample (n=5). The number of mast cells was measured in the entire area of each section (19.05x25.4 cm) for each sample (n=5).

IgE concentrations in plasma, as detected by ELISA. Blood was allowed to clot for 30 min at room temperature. The serum was prepared by centrifugation (10,000 x g for 10 min at room temperature) and stored at -70°C until use. The concentrations of IgE in serum were determined using a Mouse IgE ELISA kit (cat. no. 555248; BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's protocol.

Cluster of differentiation (CD)4+ cell expression, as detected by immunohistochemistry (IHC). IHC was performed according to the manufacturer's protocol. To retrieve antigens in the skin tissues, the deparaffinized sections were boiled in 10 mM sodium citrate buffer for 30 min. Endogenous peroxidase was subsequently blocked by incubation in 3% H2O2 for 30 min and slides were blocked with 5% normal goat serum (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) in phosphate-buffered saline (PBS) containing 5% fetal bovine serum (Corning, Inc., Corning, NY, USA), 2% bovine serum albumin (BSA; Vector Laboratories, Burlingame, CA, USA) and 0.1% Triton X-100 for 1 h. Following washing in PBS three times, the sections were incubated overnight with an antibody against biotin anti-mouse CD4 (cat. no. 100403; BioLegend, Inc., San Diego, CA, USA), diluted 1:100 in normal goat serum, in a humidified chamber. After washing with PBS, the biotinylated goat anti-mouse IgG (cat. no. BA-9200; diluted 1:200 in TBST;Vector Laboratories) was applied for 2 h at room temperature. The slides were subsequently incubated with an Avidin/Biotinylated Enzyme Complex kit (Vector Laboratories) for 1 h, followed by the substrate chromogen (3,3-diaminobenzidine; Dako, Glostrup, Denmark), and counterstained by hematoxylin staining. CD4 staining was visualized using LAS (magnification, x200).

RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR). To detect mRNA expression levels of various inflammatory cytokines, RT-PCR was performed. Total RNA was extracted from excised dorsal skin using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol, and quantified by determining the optical density at a wavelength of 260 nm. Isolated total RNA (1 µg) was used as a template for cDNA synthesis. RT was performed using a cDNA Synthesis kit (Invitrogen) for 1 h, followed by the substrate chromogen (3,3-diaminobenzidine; Dako, Glostrup, Denmark), and counterstained by hematoxylin staining. CD4 staining was visualized using LAS (magnification, x200).
sequences of primers are presented in Table I. Amplicons were visualized on 2% agarose gel stained with ethidium bromide using a GDS-200D Gel Image System version PSRem164 (UVP, Inc., CA, USA). All mRNA levels were normalized to the housekeeping gene GAPDH by a computerized densitometry system (ImageJ version 1.38e; National Institutes of Health, Bethesda, MD, USA).

**Analysis of inflammatory protein expression by western blot analysis.** To determine the mechanisms underlying the development of AD-like skin lesions, the protein expression levels of the pro-inflammatory mediators, such as nuclear factor (NF)-κB, phosphorylated (p)-inhibitor of (I)κBα and p-mitogen-activated protein kinases (MAPKs) were examined in skin homogenates. To detect p-IκBα the dorsal skin samples were homogenized by the addition of the cytoplasmic buffer [10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol (DTT), 0.5% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM NaF and 5 mM Na$_2$VO$_4$] containing protease inhibitors. The cytoplasmic protein extracts were collected following sample centrifugation at 10,000 x g for 30 min at 4°C. Cytoplasmic proteins were collected from the supernatant, and nuclear lysis buffer (20 mM HEPES at pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM NaF and 5 mM Na$_2$VO$_4$) was added to the pellet, homogenized for 20 min, and centrifuged at 16,000 x g for 30 min at 4°C. The resultant homogenate was carefully removed without disturbing the pellet for assay of activated NF-κB. The protein expression levels of the MAPKs extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinase (JNK) and p38 were confirmed in whole extracts using radioimmunoprecipitation assay containing a protease inhibitor cocktail. The cytoplasmic, nuclear and whole protein extracts were subsequently used for western blotting. Proteins were quantified by the bicinchoninic acid method according to the manufacturer's protocol (Pierce; Thermo Fisher Scientific, Inc.). The proteins (30 μg) were resolved in 10% SDS-PAGE gels and electroblotted onto polyvinylidene difluoride membranes. The membranes were blocked with 5% BSA for 1 h at room temperature and incubated with antibodies against β-actin (cat. no. sc-47778; Santa Cruz Biotechnology, Inc.), lamin-B (cat. no. sc-374015; Santa Cruz Biotechnology, Inc.), Erk1/2 (cat. no. sc-47778; Santa Cruz Biotechnology, Inc.), p-ERK1/2 (cat. no. 8404; Santa Cruz Biotechnology, Inc.), JNK1/2 (cat. no. 4695; Cell Signaling Technology, Inc.), p-JNK (cat. no. 9252; Cell Signaling Technology, Inc.), p-JNK (cat. no. 9251; Cell Signaling Technology, Inc.), p-p38 (cat. no. 9212; Cell Signaling Technology, Inc.) and p-p38 (cat. no. 4631; Cell Signaling Technology, Inc.), diluted 1:1,000 in TBS containing Tween-20 (TBST) for overnight at 4°C. Membranes were subsequently incubated with a horseradish peroxidase-conjugated secondary anti-mouse antibody (cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) and anti-rabbit antibody (cat. no. sc-2004; Santa Cruz Biotechnology, Inc.) diluted 1:2,000 in TBST for 2 h at room temperature. The immunoreactive proteins were detected with an Enhanced Chemiluminescence reagent (Pierce; Thermo Fisher Scientific, Inc.). Band intensities were quantified by a computerized densitometry software ImageJ version 1.38e.

**Statistical analysis.** Data are expressed as the mean ± standard deviation. Comparisons between the values for different variables were analyzed by one-way analysis of variance followed by Dunnnett's t-test. P<0.05 was considered to indicate a statistically significant difference using a GraphPad PRISM 5 software version 5 (GraphPad Software, Inc., La Jolla, CA, USA).

| Target gene                  | Direction | Sequence (5’-3’)              | Amplicon size (bp) |
|------------------------------|-----------|--------------------------------|-------------------|
| Interferon-γ                 | Forward   | AGCGGCTGACTGAACTCAGATTGTAG    | 330               |
| Interleukin-4                | Forward   | ATGGGTTCAACCCCCCAGC           | 300               |
| Interleukin-6                | Forward   | ATCAACTCTTCTCCACAAGGC         | 628               |
| Interleukin-8                | Forward   | TGTGGGAGGCTGTGGTTTGT          | 200               |
| Tumor necrosis factor-α      | Forward   | GGTTGGAATGCAGACCTCC           | 173               |
| Interleukin-1β               | Forward   | CTCTAGACCATGTCAGAC            | 291               |
| GAPDH                        | Forward   | GGCACTGGACCTGTGTCATGA         | 376               |
|                             | Reverse   | TTTGGGAGGCTGTGGTTTGT          | 376               |
|                             | Reverse   | ACGAGACCAGGAGAAACAGG          | 376               |
|                             | Reverse   | CAGTGATGTAGCGACAGCTTCC        | 376               |
|                             | Reverse   | TTGGGAGGCTGTGGTTTGT           | 200               |
|                             | Reverse   | ACGAGACCAGGAGAAACAGG          | 376               |
|                             | Reverse   | CAGTGATGTAGCGACAGCTTCC        | 376               |
|                             | Reverse   | TTGGGAGGCTGTGGTTTGT           | 376               |

Table I. Primer sequences used for reverse transcription polymerase chain reaction.
PH treatment reduces dorsal skin thickness. To evaluate AD symptoms, histological analysis was performed on the dorsal skin of each group (Fig. 1A). Repeated DNBC-treatment caused a thickening of the epidermis and dermis (P<0.001). Topically applied 1 and 100 mg/ml PH suppressed epidermal hyperplasia and dermal thickening, as did 10 µM DEX. Quantitative analysis revealed that the PH1, PH100 and DEX groups (P<0.001) demonstrated a 27.4, 44.6 and 47.2% reduction in epidermal thickness (Fig. 1B). In addition, 12.3, 27.0 and 27.1% reduction of dermal thickness was observed in PH1 (P<0.01), PH100 (P<0.01) and DEX (P<0.001; Fig. 1C).

PH inhibits the infiltration of mast cells into the dermis. DNBC-treated skin lesions (P<0.001) revealed increased infiltration of mast cells compared with the NOR group (Fig. 2A and B). Topical application of PH1, PH100 or DEX markedly decreased this infiltration (P<0.001).

PH reduces serum IgE levels. The concentration of IgE in the plasma of the NOR group was 143.4±51.49 ng/ml. This increased to 4348.0±446.05 ng/ml in the DNBC group (P<0.001; Fig. 2C). The serum IgE levels in the PH1, PH100 and DEX groups was reduced ~1.4-, ~3.7- and ~2.2-fold compared with the DNBC group (P<0.001).

PH suppresses the infiltration of CD4+ cells. To examine the accumulation of CD4+ cells in allergic inflamed skin, the expression of CD4 in dorsal skin sections was detected by IHC (Fig. 3). Increased immunostaining was observed in the DNBC group compared with the NOR group. The detection of CD4 expression was markedly reduced in mice treated with PH1, PH100 or DEX compared with the DNBC group.

PH inhibits the mRNA expression levels of Th1 and Th2 cytokines in dorsal skin lesions. To elucidate the effect of PH treatment on cytokine expression, alterations in the mRNA expression levels of various cytokines were analyzed, including Th1-specific (IFN-γ), Th2-specific (IL-4) and pro-inflammatory (IL-6, IL-8, TNF-α and IL-1β) cytokines (Fig. 4). The DNBC group (P<0.001) expressed increased expression levels of Th1 and pro-inflammatory cytokine mRNA in skin tissues compared with the NOR group. PH (1 and 100 mg/ml) and DEX suppressed the Th1 and pro-inflammatory cytokine mRNA production stimulated by DNBC application. The inhibitory effects of the PH1, PH100 and DEX groups were as follows: 32.5, 51.0 and 47.7% for IFN-γ (PH1 and PH100; P<0.001); 26.8, 36.2 and 27.5% for TNF-α (PH1, P<0.01; PH100, P<0.001); and 14.7, 29.8 and 44.2% for IL-1β (PH100, P<0.001), respectively. Similarly, the mRNA expression levels of IL-4, IL-6 and IL-8 markedly increased following DNBC application compared with the NOR group.
Figure 2. *Pseudostellaria heterophylla* decreases the number of mast cells in dorsal skin and serum IgE levels. (A) Mast cells were detected by toluidine blue staining. Magnification, x100; scale bar=200 µm. (B) Infiltration of mast cells was quantified by counting the mast cells in the slides (n=5). (C) Serum levels of IgE were measured by ELISA. Data are presented as the mean ± standard deviation (n=5). ###P<0.001 vs. NOR; ***P<0.001 and **P<0.01 vs. DNCB. NOR, vehicle-treated mice; DNCB, 2,4-dinitrochlorobenzene-treated mice; DEX, 2,4-dinitrochlorobenzene- and dexamethasone-treated mice; PH1, 2,4-dinitrochlorobenzene- and 1 mg/ml *Pseudostellaria heterophylla*-treated mice; PH100, 2,4-dinitrochlorobenzene- and 100 mg/ml *P. heterophylla*-treated mice; IgE, immunoglobulin E.

Figure 3. *Pseudostellaria heterophylla* suppresses the infiltration of CD4⁺ T cells into dorsal skin. Representative images revealing CD4 staining, as detected by immunohistochemistry. Magnification, x100; scale bars=200 µm. NOR, vehicle-treated mice; DNCB, 2,4-dinitrochlorobenzene-treated mice; DEX, 2,4-dinitrochlorobenzene- and dexamethasone-treated mice; PH1, 2,4-dinitrochlorobenzene- and 1 mg/ml *Pseudostellaria heterophylla*-treated mice; PH100, 2,4-dinitrochlorobenzene- and 100 mg/ml *P. heterophylla*-treated mice; CD, cluster of differentiation.
PH decreases the protein expression levels of NF-κB, p-IκBα and MAPKs in dorsal skin lesions. The expression of inflammatory cytokines is regulated by the transcription factor p65 NF-κB. PH treatment (1 and 100 mg/ml) inhibited the nuclear translocation of p65 NF-κB about 34.4 and 56.0%, respectively (P<0.001). DEX group showed 50.4% reduction of NF-κB protein expression (P<0.001). Also, p-IκBα expressions in PH1 (P<0.05), PH100 (P<0.001) and DEX (P<0.001) groups were significantly decreased (Fig. 5A). Similarly, the protein expression levels of p-ERK1/2 (P<0.001, Fig. 5B), p-p38 (P<0.01, Fig. 5C) and p-JNK (P<0.001, Fig. 5D) were dose-dependently downregulated following PH treatment.

Discussion

The present study demonstrated an immunomodulatory effect of PH against AD progression and elucidated the underlying mechanism of action. The morphology of the DNCB-induced AD model revealed increased epidermal thickening and dermal infiltration of CD4+ T cells and mast cells, consistent with AD skin lesions. Repeated treatment with PH effectively improved the symptoms of AD by reducing hyperkeratosis and hyperplasia in the epidermis and dermis.

The high levels of IgE measured in AD are associated with the activation of underlying inflammatory cascades (13). In addition, mast cells exhibit immunomodulatory activity via cross-talk with various biological mediators involved in IgE-mediated AD (14, 15). Therefore, the present study investigated whether topical treatment of PH affected the serum level of IgE and the infiltration of mast cells. The DNCB group expressed the greatest levels of IgE in serum and numbers of mast cells in skin. Topical application of 1 and 100 mg/ml PH suppressed serum IgE levels by 30.9 and 73.2%, respectively. The reduction of IgE concentrations is consistent with the suppression of mast cell infiltration into the dermis following PH treatment.

T cells are crucial for immune responses, and the dysregulation of the CD4+ T cell subset is an important aspect of AD pathophysiology (16). A previous study determined that CD4+ T cells increased in numbers in the AD-like skin lesions in DNCB-induced mice model (17). Accordingly, the elevation of CD4 expression in the dermis may suggest that Th1 and Th2 cells are involved (4). The present study revealed that PH suppressed increases in CD4+ T cell numbers, were assumed to be CD4+ T cells in the skin. Activated CD4+ T cells have two distinct subfamilies, Th1 cells and Th2 cells, classified by the cytokines they secrete. The topical treatment of PH significantly suppressed the expression levels of Th1-(IFN-γ) and Th2-(IL-4 and -6) specific cytokines. In addition, IFN-γ may
contribute to the proliferation and differentiation of infiltrating macrophages, which may aggravate AD-like skin lesions (18). The reduction of IFN-γ expression levels may be associated with the immunosuppressive effects of PH, via inhibition of macrophage recruitment to the site of inflammation. Th2 cells produce IL-4 and -6, and are associated with cell and membrane destruction in acute atopic dermatitis (19,20). PH treatment decreased the increased expression levels of IL-4 and -6 induced by DNCB application.

The modulating effect of PH on Th1 and Th2 immune responses appears to have been demonstrated by the effects on serum IgE levels. In addition, overexpression of IL-8, TNF-α and IL-1β may be associated with a high number of infiltrated macrophages and basophils in the dermis (21). Topical treatment with PH significantly reduced IL-8, TNF-α and IL-1β expression levels and these findings were more pronounced in the PH100 group.

NF-κB is critical for inflammatory cytokine transcriptional regulation and is important for immune responses. The activation of the NF-κB signaling pathway results in the phosphorylation and therefore degradation of IκB (22). In the DNCB-induced mouse model of the present study, PH inhibited the phosphorylation of IκBα and the nuclear translocation of NF-κB. In addition, MAPKs represent a critical signaling cascade in immune responses, interacting with NF-κB to regulate inflammation (23,24). In the present study, DNCB-induced phosphorylation of all three MAPKs was reduced by PH treatment. These results support the hypothesis that the inhibitory effects of PH on pro-inflammatory cytokine expression are due to suppression of the MAPK and NF-κB signaling pathways.

In conclusion, the results of the present study demonstrated a reduction in the pathological features of AD, including dorsal skin thickness, mast cell infiltration and release of IgE following treatment with PH, supporting the clinical potential of PH as an alternative therapeutic strategy for the management of AD. The inhibition of Th1 and Th2 inflammatory cytokines suggests that PH may exert anti-AD activity by regulating a series of immune pathological events, including the expression of NF-κB, p-IκBα and MAPKs. PH may therefore affect Th1/Th2 immune dysregulation, leading to the suppression of the features of AD.

Acknowledgements

The present study was supported by the National Research Foundation of Korea funded by the Korean government (grant no. NRF-2015R1A4A1042399).
References

1. Levy ML: Atopic dermatitis: Understanding the disease and its management. Curr Med Res Opin 23: 3091-3103, 2007.

2. Minnicozzi M, Sawyer RT and Fenton MJ: Innate immunity in allergic disease. Immunol Rev 242: 106-127, 2011.

3. Mosmann TR and Coffman RL: Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173, 1989.

4. Leung DY, Boguniewicz M, Howell MD, Nomura I and Hamid QA: New insights into atopic dermatitis. J Clin Invest 113: 651-657, 2004.

5. Nakamura K: Pathogenesis and treatment of allergic skin disease-atopic dermatitis. Aeriugi 64: 703-706, 2015 (In Japanese).

6. Liu J, Pei M, Zheng C, Li Y, Wang Y, Lu A and Yang L: A systems-pharmacology analysis of herbal medicines used in health improvement treatment: Predicting potential new drugs and targets. Evid Based Complement Alternat Med 2013: 938764, 2013.

7. Ng TB, Liu F and WangHX: The antioxidant effects of aqueous and organic extracts of panax quinquefolium, panax notoginseng, codonopsis pilosula, pseudostellaria heterophylla and glehnia littoralis. J Ethnopharmacol 93: 285-288, 2004.

8. Pang W, Lin S, Dai Q, Zhang H and Hu J: Antitussive activity of pseudostellaria heterophylla (miq.) pax extracts and improvement in lung function via adjustment of multi-cytokine levels. Molecules 16: 3360-3370, 2011.

9. Li X, Chen Y, Lai Y, Yang Q, Hu H and Wang Y: Sustainable utilization of traditional chinese medicine resources: Systematic evaluation on different production modes. Evid Based Complement Alternat Med 2015: 218901, 2015.

10. Li Y and Yang XW: Studies on chemical constituents of root tuber of cultivated pseudostellaria heterophylla (Zheshen No. 1). Zhongguo Zhong Yao Za Zhi 33: 2353-2355, 2008 (In Chinese).

11. Wong CK, Leung KN, Fung MC, Fung KP and Choy YM: The induction of cytokine gene expression in murine peritoneal macrophages by pseudostellaria heterophylla. Immunopharmacol Immunotoxicol 16: 347-357, 1994.

12. Choi YY, Kim MH, Hong J, Kim K and Yang WM: Effect of Danagubohylay-Tang, a mixed extract of astragalus membranaceus and angelica sinensis, on allergic and inflammatory skin reaction compared with single extracts of astragalus membranaceus or angelica sinensis. Evid Based Complement Alternat Med 2016: 5936354, 2016.

13. Shin HS, See HJ, Jung SY, Choi DW, Kwon DA, Bae MJ, Sung KS and Shon DH: Turmeric (curcuma longa) attenuates food allergy symptoms by regulating type 1/type 2 helper t cells (th1/th2) balance in a mouse model of food allergy. J Ethnopharmacol 175: 21-29, 2015.

14. Kang H, Lee CH, Kim JR, Kwon JY, Seo SG, Han JG, Kim BG, Kim JE and Lee KW: Chlorella vulgaris attenuates dermatophagoides farinae-induced atopic dermatitis-like symptoms in ncutgamma mice. Int J Mol Sci 16: 21021-21034, 2015.

15. Park S, Kim da S, Kang S and Shin BK: Synergistic topical application of salt-processed phellobidendron amurense and sanguisorba officinalis linne alleviates atopic dermatosis symptoms by reducing levels of immunoglobulin e and pro-inflammatory cytokines in ncunga mice. Mol Med Rep 12: 7657-7664, 2015.

16. Vocanson M, Hennino A, Chavagnac C, Saint-Mezard P, Dubois B, Kaiserlian D and Nicolau JF: Contribution of cd4(+) and cd8(+) T-cells in contact hypersensitivity and allergic contact dermatitis. Expert Rev Clin Immunol 1: 75-86, 2005.

17. Zhang EY, Chen AY and Zhu BT: Mechanism of dinitrochlorobenzene-induced dermatitis in mice: Role of specific antibodies in pathogenesis. PLoS One 4: e7703, 2009.

18. Lee HS, Kim SK, Han J, Choi HM, Park JH, Kim EC, Choi MS, An HJ, Um JY, Kim HM and Min BI: Inhibitory effects of Rumex japonicus Houtt. On the development of atopic dermatitis-like skin lesions in Nc/Nga mice. Br J Dermatol 155: 33-38, 2006.

19. Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar BS and Chan LS: Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 138: 375-387, 2004.

20. Lee HJ, Lee HP, Ha SJ, Byun DG and Kim JW: Spontaneous expression of mrna for il-10, GM-CSF, TGF-beta, TGF-alfa, and IL-6 in peripheral blood mononuclear cells from atopic dermatitis. Ann Allergy Asthma Immunol 84: 535-538, 2000.

21. Szegedi K, Lutter R, Bos JD, Luiten RM, Kezic S and Vocanson M: Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol 29: 2136-2144, 2015.

22. Li W, Zhao Y, Xu X, Ma W, Guo P, Wang Y, Liang K and Li R: Rebamipide suppresses TNF-α mediated inflammation in vitro and attenuates the severity of dermatitis in mice. FEBS J 282: 2317-2326, 2015.

23. Lee J, Choi YY, Kim MH, Han J, Lee JE, Kim EH, Hong J, Kim J and Yang WM: Topical application of angelica sinensis improves pruritus and skin inflammation in mice with atopic dermatitis-like symptoms. J Med Food 19: 98-105, 2016.

24. Mishra S, Tripathi A, Chaudhari BP, Dwivedi PD, Pandey HP and Das M: Deoxyxynivalenol induced mouse skin cell proliferation and inflammation via MAPK pathway. Toxicol Appl Pharmacol 279: 186-197, 2014.